Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Gannett Sends Open Letter to Shareholders

Published

on

Reading Time: 8 minutes

Unanimously Recommends that Shareholders Vote “FOR ALL” of Gannett’s
Eight Experienced, Engaged and Independent Director Nominees on the
WHITE Proxy Card

MCLEAN, Va.–(BUSINESS WIRE)–Gannett Co., Inc. (NYSE: GCI) today sent an open letter to shareholders
urging shareholders to vote “FOR ALL” of the company’s highly
experienced, fully independent director nominees on the WHITE proxy card
in connection with Gannett’s 2019 annual meeting of shareholders
scheduled to be held on May 16, 2019.

The full text of the letter follows below:

Dear Fellow Shareholder,

At the upcoming Annual Meeting on May 16, 2019, you will make a very
important decision regarding the composition of the Gannett board that
will shape the future of the company and have a lasting impact on the
value of your investment.

In recent weeks, we have appreciated having the opportunity to speak
with many of you about our ongoing digital transformation and the
progress we are seeing, as well as the efforts by MNG Enterprises, Inc.
(“MNG”), a direct competitor of Gannett, and its majority shareholder
Alden Global Capital (“Alden”) to take control of the company by
installing their own directors, officers, colleagues and friends on the
Gannett board – all while touting an unsolicited proposal to buy Gannett
that they cannot finance or close. Now, in a last-ditch, desperate
effort, MNG has announced that it is reducing the number of candidates
that it is nominating for election to Gannett’s eight-member board from
six to three.

Importantly, the number of MNG nominees does not matter, as each of the
three remaining MNG candidates still has irreconcilable conflicts of
interest given each nominee’s close affiliations with MNG and/or Alden,
and cannot be expected to act in the best interests of all Gannett
shareholders. Further, MNG’s candidates have backgrounds and skillsets
that we believe would not be additive to the Gannett board, and, indeed,
would reduce the quality of the Gannett board to the detriment of both
the company and its shareholders. In contrast, all eight of Gannett’s
director nominees are FULLY independent and bring broad and diverse
backgrounds, professional experience and skills in areas that are
critical to Gannett’s business and future success. We believe that
electing even one of MNG’s nominees to the Gannett board would put the
value of your investment at risk.

Your vote is very important. We encourage you to protect the value of
your investment in Gannett by voting “FOR ALL” of your board’s eight
independent nominees on the WHITE proxy card today.

MNG’S CANDIDATES ARE HIGHLY CONFLICTED

All of MNG’s candidates have clear conflicts of interest, which we
believe would prevent them from being able to meaningfully fulfill their
duties as Gannett directors:

  • Heath Freeman is the president and a founding member of Alden,
    vice chairman of MNG and chairman of the board of Fred’s, Inc., where
    he was appointed to the board pursuant to a Cooperation Agreement
    between Fred’s and Alden.
  • Steven Rossi was CEO of MNG until his retirement in November
    2017 and currently serves as a director on the Fred’s board after
    being appointed to the board pursuant to the same Cooperation
    Agreement as Mr. Freeman.
  • Dana Goldsmith Needleman is also a director of Fred’s, as well
    as a family friend of Mr. Freeman. They have known each other for
    years prior to Ms. Needleman being hand-picked to serve on the Fred’s
    board, including through business dealings, charitable organizations,
    a shared alma mater and documented social gatherings. Further, Ms.
    Needleman’s spouse represented Alden in real estate dealings, and Ms.
    Needleman made a sizeable personal donation to one of their alma
    mater’s organizations where Mr. Freeman is chairman of the advisory
    board. In short, it cannot reasonably be concluded that Ms. Needleman
    has “no material relationship” with Alden, and she is therefore NOT
    independent of MNG.

Because of the significant and concerning conflicts of interest
resulting from MNG’s candidates’ affiliations with a direct competitor
and/or the controlling owner of a direct competitor, MNG’s candidates
may face significant restrictions on the company information to which
they could have access, meaning they could not benefit from the same
information available to Gannett’s independent director nominees and
would not be able to participate fully in decisions critical to creating
value for our shareholders.

MNG’S CANDIDATES WOULD REDUCE THE QUALITY OF THE GANNETT BOARD

As part of the board’s nomination process this year, the Nominating and
Public Responsibility Committee and the full Gannett board reviewed
MNG’s six proposed nominees, and unanimously concluded that NONE would
bring incremental expertise to the board, and indeed would worsen the
quality of the board in terms of skills and experience.

Mr. Freeman, Mr. Rossi and Ms. Needleman have nearly no public board
experience outside of serving together on the board of Fred’s, the
Alden-controlled regional pharmacy chain. At Fred’s, they have overseen
significant value destruction – with Fred’s stock declining 92% since
Alden invested in December 2016, despite Fred’s operating in a steadily
growing market.1 Mr. Freeman’s only other public board
experience was at Emmis Communications Corp in 2010, where he was
appointed not due to his qualifications but instead in connection with
an Alden agreement to take Emmis private. He resigned a few months later
after Alden pulled out of the deal.

In contrast, all of Gannett’s independent nominees, including the three
nominees MNG is seeking to replace, have a wealth of professional
experience and expertise critical to Gannett’s operations and digital
transformation, including finance, business development and strategic
planning, M&A, digital media, journalism, marketing and advertising,
technology and human resources. While MNG claims that it wants to focus
on Gannett’s publishing business, MNG is now attempting to replace
three directors on Gannett’s board, including two distinguished
journalists, Stephen Coll and Larry Kramer, with a hedge fund president,
a real estate dealmaker and a propane company manager turned newspaper
executive without any background in journalism
.

MNG’S INTERESTS ARE NOT ALIGNED WITH THOSE OF OTHER SHAREHOLDERS AND
MNG’S FALSE AND MISLEADING STATEMENTS SEEK ONLY TO ADVANCE ITS
INTERESTS, NOT THOSE OF ALL SHAREHOLDERS

Contrary to MNG’s claims, MNG has NOT demonstrated an ability to
position acquired newspapers for long-term profitability. It has been
widely documented that MNG has drastically reduced jobs at its
newspapers, thereby undercutting the papers’ ability to produce quality
journalism and retain subscribers. Once subscribership falls due to lack
of meaningful content, MNG responds with yet more cost cuts, and in some
cases, closures of the papers all together.

In addition to MNG’s baseless claims of having executed revivals of
print newspapers, MNG is intentionally misleading shareholders in its
calculations of Gannett’s performance and the illusory premium it offers
shareholders. Even after Gannett clearly identified flaws in MNG’s
calculations, MNG continues to make the same claims:

  • MNG compares Gannett’s 2018 results to a time when Gannett was not
    even a standalone company and ignores that the company’s digital
    marketing solutions business was built beginning in the second half of
    2016, with its contribution to performance only being reflected
    thereafter.
  • MNG compares Gannett’s performance to companies outside its industry
    peer group and arbitrarily compares the “premium” of its illusory
    proposal not to Gannett’s unaffected stock price (as would be
    customary) but instead to the lowest closing price for Gannett’s
    shares in its entire 52-week range, taking advantage of the sharp
    decline the entire stock market experienced in December 2018.

GANNETT’S NOMINEES ARE COMMITTED TO ACTING IN THE BEST INTERESTS OF
ALL GANNETT SHAREHOLDERS

Your board and management team are executing a multi-year transformation
strategy to position Gannett to thrive in a digital future. We are the
first to acknowledge that transformations are hard and take time, and
that we have more work to do. That said, we are confident that the steps
we have taken – and are continuing to take – provide the best path
forward for our company to deliver value in the near term. Our focused
strategy to enhance Gannett’s growth and profitability is centered
around:

  • Leveraging our nationwide scale and local presence to expand and
    deepen our relationships with consumers and businesses;
  • Accelerating organic digital revenue growth through innovative
    consumer experiences and new marketing and advertising solutions;
  • Pursuing accretive growth through disciplined, selective acquisitions
    that provide synergies with our customer base and markets; and
  • Aligning costs within our legacy print business in a thoughtful and
    strategic manner.

The financial results our strategic initiatives have delivered to date
reflect our progress and the potential for Gannett’s digital investments
to serve as a growth engine for many years into the future. In 2018
alone, Gannett:

  • Grew digital subscribers by 46%, bringing total paid digital-only
    subscribers to over 500,000.
  • Grew ReachLocal revenues by 15%.
  • Grew national digital advertising revenue by 19%, with 75% of USA
    TODAY’s advertising revenue now digital.

Still, our board regularly evaluates our strategic options to ensure
that we are best positioned to deliver value for our shareholders.
Indeed, we have publicly stated that we would engage with any party that
makes a bona fide, credible proposal that appropriately values the
company and is capable of being closed.
MNG’s illusory proposal
continues to fail our test.

VOTE TODAY “FOR ALL” OF GANNETT’S INDEPENDENT, EXPERIENCED DIRECTOR
NOMINEES ON THE WHITE PROXY CARD

While we still have work to do, the fact is that Gannett’s USA TODAY
NETWORK strategy, digital transformation and focus on client
relationships are paying off. Our director nominees have the skills and
experience we need to continue to oversee this strategy and make the
right decisions to maximize value for all
Gannett shareholders. Importantly, all eight of your director nominees
are committed to acting in your best interests, and are not beholden to
or influenced by any outside entity. The same cannot be said about even
one of MNG’s candidates.

We believe your vote will impact the value of your investment – please
vote TODAY “FOR ALL” of Gannett’s eight independent director nominees.

We thank you for your continued support.

Sincerely,

/s/

J. Jeffry Louis, Chairman of the Gannett board of directors

 

If you have any questions, or need assistance in voting your
shares, please call the firm assisting us in the solicitation of
proxies:

 

INNISFREE M&A INCORPORATED

TOLL-FREE at 1-877-456-3507

 

Additional materials regarding the board of directors’
recommendations for the annual meeting are available on the
investor relations page of Gannett’s website at https://investors.gannett.com.

 

About Gannett

Gannett Co., Inc. (NYSE: GCI) is an innovative, digitally focused
media and marketing solutions company committed to strengthening
communities across our network. With an unmatched local-to-national
reach, Gannett touches the lives of more than 125 million people monthly
with our Pulitzer-Prize winning content, consumer experiences and
benefits, and advertiser products and services. Gannett brands include
USA TODAY NETWORK with the iconic USA TODAY and more than 100 local
media brands, digital marketing services companies ReachLocal,
WordStream and SweetIQ, and U.K. media company Newsquest. To connect
with us, visit www.gannett.com.

Forward-Looking Statements

This communication contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include all statements that are not
historical facts. The words “believe,” “expect,” “estimate,” “could,”
“should,” “intend,” “may,” “plan,” “seek,” “anticipate,” “project” and
similar expressions, among others, generally identify forward-looking
statements, which speak only as of the date the statements were made and
are not guarantees of future performance. Where, in any forward-looking
statement, an expectation or belief as to future results or events is
expressed, such expectation or belief is based on the current plans and
expectations of our management and expressed in good faith and believed
to have a reasonable basis, but there can be no assurance that the
expectation or belief will result or be achieved or accomplished.
Whether or not any such forward-looking statements are in fact achieved
will depend on future events, some of which are beyond our control. The
matters discussed in these forward-looking statements are subject to a
number of risks, trends, uncertainties and other factors that could
cause actual results or events to differ materially from those
projected, anticipated or implied in the forward-looking statements,
including the matters described under the heading “Risk Factors” and
Management’s Discussion and Analysis of Financial Condition and Results
of Operations” in the company’s annual report on Form 10-K for fiscal
year 2018 and in the company’s other SEC filings.

________________________________
1 Based on Fred’s
closing stock prices on April 18, 2019, and December 21, 2016 (the day
prior to the filing of Alden’s initial 13D). Market growth source:
Euromonitor. Statement based on 13-18 CAGR of 3% for
drugstores/parapharmacies in the U.S.

Contacts

For investor inquiries:
Stacy Cunningham
Vice
President, Financial Planning & Investor Relations
703-854-3168
[email protected]

Arthur
Crozier / Jennifer Shotwell / Larry Miller
Innisfree M&A
Incorporated
(212) 750-5833

For media inquiries:
Amber
Allman
Vice President, Corporate Events & Communications
703-854-5358
[email protected]

Ed
Trissel / Nick Lamplough / Tim Ragones
Joele Frank, Wilkinson
Brimmer Katcher
(212) 355-4449


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania